BeOne Medicines (NASDAQ:ONC) CEO Sells $15,086,671.00 in Stock

Posted by Stanley Muller on Jul 31st, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) CEO John Oyler sold 48,316 shares of the company’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $312.25, for a total transaction of $15,086,671.00. Following the completion of the sale, the chief executive officer directly owned 9,180 shares of the company’s stock, valued at $2,866,455. The trade was a 84.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The stock was sold at an average price of $317.67, for a total transaction of $19,503,984.99.
On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total transaction of $3,489,981.32.
On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total transaction of $14,767,062.00.
On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95.
On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total value of $933,589.80.
On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total value of $980,676.15.
On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.
On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Price Performance

NASDAQ:ONC opened at $322.08 on Friday. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The business’s 50-day moving average price is $293.39 and its 200 day moving average price is $309.31. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $253.95 and a 52-week high of $385.22. The firm has a market cap of $35.34 billion, a P/E ratio of 72.05 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion during the quarter. As a group, sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. EFG International AG acquired a new stake in shares of BeOne Medicines during the fourth quarter valued at approximately $25,000. Leonteq Securities AG acquired a new position in BeOne Medicines in the 4th quarter worth approximately $35,000. Daiwa Securities Group Inc. purchased a new position in BeOne Medicines during the 2nd quarter worth approximately $35,000. CWM LLC grew its position in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares in the last quarter. Finally, Group One Trading LLC acquired a new stake in BeOne Medicines during the 4th quarter valued at $61,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ONC. JPMorgan Chase & Co. raised their target price on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Nomura raised BeOne Medicines to a “strong-buy” rating in a report on Monday. Leerink Partners increased their price objective on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Friday, July 17th. Finally, Truist Financial lifted their target price on BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $394.00.

Get Our Latest Stock Report on ONC

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.